BVTS CIRCLE

BVTS YTUBE

SEARCHMEDICINA

BVTS PATRON

PLAB-2

MAILING LIST

CONTACT US

The universal GP Training website for everyone, not just Bradford.   Created in 2002 by Dr Ramesh Mehay

History of Bradford VTS

Gynaecology & Breast

Updated Guidelines 2024-2026:

NICE menopause guideline (NG23) revised November 2024 with updated HRT evidence. Fezolinetant (Veoza®) NICE-approved March 2026 for vasomotor symptoms when HRT unsuitable. New age-adjusted CA125 thresholds proposed for ovarian cancer detection (January 2026). Suspected cancer pathways updated May 2025 with refined two-week wait criteria.

Breast & Gynaecology for GPs: Your Essential Guide

From lumps to hot flushes — because every consultation deserves confidence, not panic

☕ Tea-Friendly Learning ⏰ For GP Trainees Short on Time 🚩 Red Flag Focused

Last Updated: 22 March 2026

Executive Summary: What You'll Master Today

Because you have 47 other things to do before lunch, and that's just the morning list

Quick Facts at a Glance:

1 in 7
Women develop breast cancer in their lifetime
~77%
10-year survival overall; nearly 100% if caught at stage 1
1 in 50
Women with ovarian cancer by age 75
7 years
Average duration of menopausal symptoms

📥 Downloads & Resources

Useful downloads and web links for breast and gynaecology

📥 Downloads

path: Breast & Gynaecology

This shortcode is replaced automatically by WordPress.

🌐 Web Resources

📚 Quick Navigation

📋 Data Gathering 🔍 Diagnostic Approach 🎯 Differentials 💊 Common Conditions 🚩 Red Flags 🏥 Referral & Safety-Netting 💬 Communication Skills 🛡️ Prevention & Screening 🤝 MDT & Services 📚 MRCGP Exam Focus

🧠 Brainy Bites: Essential Breast & Gynaecology Wisdom

The stuff seasoned GPs wish someone had told them sooner

💡
The Triple Assessment Rule — For any breast lump: Clinical exam + Imaging (USS <40yrs, mammogram ≥40yrs) + Tissue diagnosis (FNA/core biopsy). Never rely on one modality alone — even normal imaging doesn't exclude cancer if clinical suspicion remains.
🔑
Painless Lump = More Suspicious — A painless breast lump is MORE worrying for malignancy. Most breast cancers are painless. Never be falsely reassured because "it doesn't hurt." Always proceed with triple assessment for any discrete lump regardless of pain.
⚠️
Woman ≥60 + Abdominal Swelling = Think Ovarian Cancer — A postmenopausal woman saying "I'm getting fatter around my tummy" may have ovarian cancer, not middle-age spread. Check CA125, arrange pelvic USS, and examine abdomen. Don't attribute abdominal distension to weight gain without investigation.
🩺
What Does Dyspareunia Tell You? — Superficial dyspareunia (pain at entry): vaginal atrophy/dryness (very common postmenopausally, treat with vaginal oestrogen), infection, vaginismus, vulvodynia. Deep dyspareunia: endometriosis (classic), PID, fibroids, ovarian cysts. Always ask — most patients won't volunteer it.
🧠
Perimenopause Masquerades as Depression — Any woman around 50 with fatigue, low mood, brain fog, anxiety, or poor concentration should prompt you to think: could this be perimenopause? Women are frequently started on antidepressants for what is actually unrecognised perimenopause. HRT, not SSRIs, should often be first-line for mood symptoms in perimenopausal women without a prior history of depression (NICE NG23 2024).
🎯
Micronised Progesterone (Utrogestan) Is the Safest Progestogen — When prescribing combined HRT, choose Utrogestan® (micronised progesterone) over synthetic progestogens wherever possible. It is body-identical, has a significantly more favourable breast cancer risk profile than norethisterone or MPA, and is better tolerated. Combined HRT with synthetic progestogen adds ~4 extra breast cancer cases per 1,000 women over 5 years; with micronised progesterone the risk appears near-neutral.
🚫
Wild Yam Cream Cannot Protect the Womb — Wild yam (diosgenin) CANNOT be converted into progesterone by the human body without laboratory processing. Wild yam creams provide NO endometrial protection for women taking oestrogen — a potentially dangerous misconception. The body-identical HRT we prescribe on the NHS (Ovestin gel, Utrogestan) IS made from plant sources, properly processed. This is the real "natural" option.
🆕
Fezolinetant (Veoza®) — New NICE-Approved Treatment March 2026 — A new non-hormonal option for moderate-to-severe vasomotor symptoms when HRT is medically unsuitable or not desired. 45mg once daily. Mechanism: NK3 receptor antagonist (blocks hypothalamic neurokinin B pathway). Reduces hot flush frequency by ~60%. Requires LFT monitoring (hepatotoxicity signal in trials). Not for use alongside HRT.
⚠️
HRT is NOT a Contraceptive — Women in perimenopause still need contraception. Continue contraception for 1 year after last period if over 50, 2 years if under 50. The Mirena 52mg IUS is excellent — it provides both endometrial protection for HRT AND contraception. POI does not reliably prevent pregnancy (5-10% conceive spontaneously).
🔑
No Arbitrary 5-Year HRT Limit — NICE is clear: there is no mandatory time limit on HRT use. Menopausal symptoms last an average of 7 years and can persist for decades. Duration should be based on individual annual risk-benefit assessment. Women should not be told they must stop at 5 years — this is not evidence-based.
💊
CA125 Age-Adjusted Thresholds (2026 Update) — New NICE guidance proposes age-specific CA125 cut-offs: <50yrs use >35 U/mL, ≥50yrs use >70 U/mL. Reduces false positives in premenopausal women while maintaining sensitivity for postmenopausal ovarian cancer detection.
📋
Ovarian Cancer's Vague Presentation — The classic triad: persistent bloating + early satiety + pelvic/abdominal pain (>12 times/month). In women ≥60, abdominal distension is ovarian cancer until proven otherwise. Most women with ovarian cancer had these symptoms first — and most were initially missed.
🩺
Pelvic Exam Etiquette — Always offer chaperone (document if declined). Explain each step before doing it. Use "I'm going to..." not "Can I...". Warm speculum. Never assume consent from previous exams. Trauma-informed care is standard care.

1️⃣ Data Gathering in Breast & Gynaecology

Structured approach to history, examination, and investigations

Comprehensive Data Gathering Framework

Systematic approach to breast and gynaecological presentations

Presenting Complaint: Onset, duration, progression, associated symptoms, impact on daily life. For breast symptoms: relation to menstrual cycle. For gynaecological symptoms: last menstrual period, pregnancy status.

•Breast Lump: When noticed, size change, painless vs painful (painless = MORE suspicious), skin changes, nipple discharge, axillary lumps
•Breast Pain: Cyclical vs non-cyclical, unilateral vs bilateral, severity (0-10). Breast pain alone (no lump) is cancer in <1% of cases — but always examine.
•Vaginal Bleeding: Pattern (IMB/PCB/PMB), volume, clots, associated pain, discharge
•Pelvic Pain / Dyspareunia: Superficial (atrophy, infection, vaginismus) vs deep (endometriosis, PID, fibroids). Always ask — patients rarely volunteer dyspareunia.
•Abdominal Swelling (women ≥60): Do not attribute to weight gain — investigate for ovarian cancer (CA125 + pelvic USS).

⚠️ Red Flag Questions: Unexplained weight loss, night sweats, persistent symptoms >3 weeks, postmenopausal bleeding, palpable mass, family history of breast/ovarian cancer (especially BRCA)

✅ ICE Exploration: "What are you most worried this might be?" "How is this affecting your life?" "What would help most right now?"

Breast Examination: Inspect (asymmetry, skin changes, nipple inversion), palpate (all quadrants + axillae + supraclavicular). Best performed days 7-14 of cycle.

•Inspection: Arms by side, then raised, then hands on hips. Look for asymmetry, skin dimpling, peau d'orange, nipple changes
•Palpation: Systematic quadrant examination (supine, arm behind head). Note size, shape, consistency, mobility, tenderness, skin tethering
•Lymph Nodes: Axillary (5 groups), supraclavicular, infraclavicular. Document size, consistency, mobility

🩺 Pelvic Examination: Always offer chaperone. Explain each step. Inspect vulva (atrophy, lesions). Speculum (cervix, discharge, bleeding). Bimanual (uterine size/mobility, adnexal masses, cervical excitation).

⚠️ When NOT to Examine: During menstruation (breast), if patient declines (document), if examination unlikely to change management. Never assume consent from previous exams.

Breast Imaging: USS <40yrs (dense breast tissue), mammogram ≥40yrs. Never rely on imaging alone — clinical suspicion overrides normal imaging.

•Ultrasound: First-line <40yrs. Distinguishes solid vs cystic. Guides biopsy. Can miss microcalcifications
•Mammogram: First-line ≥40yrs. Detects microcalcifications. Less sensitive in dense breasts. Screening 50-71 every 3 years

💊 Gynaecological Investigations: Pregnancy test (always!), pelvic USS, CA125 (age-adjusted thresholds), endometrial biopsy (PMB), cervical smear (if due), STI screen

✅ CA125 Age-Adjusted (2026): <50yrs use >35 U/mL, ≥50yrs use >70 U/mL. Reduces false positives in premenopausal women.

2️⃣ Diagnostic Approach & Triple Assessment

Structured pathways for breast and gynaecological presentations

Triple Assessment for Breast Lumps

Gold standard diagnostic pathway — never rely on one modality alone

Clinical Assessment (P1): History + examination. Classify as benign, suspicious, or malignant. Document size, location, consistency, mobility, skin changes, lymphadenopathy.

•Benign Features: Smooth, mobile, well-defined, soft/rubbery, bilateral, cyclical pain, <35yrs
•Suspicious Features: Hard, irregular, fixed, skin tethering, nipple inversion, axillary nodes, >50yrs. Painless = more suspicious
•Malignant Features: Rock hard, very irregular, skin ulceration, peau d'orange, bloody nipple discharge, fixed axillary nodes

🛑 Critical Rule: Even if clinical assessment suggests benign, complete triple assessment is mandatory for any discrete lump. Up to 10% of cancers have benign clinical features. Painless does NOT mean safe.

Imaging (P2): USS <40yrs (dense breasts), mammogram ≥40yrs. Specialist decides modality.

ModalityBest ForLimitations
Ultrasound<40yrs, cyst vs solid, biopsy guidanceMisses microcalcifications, operator-dependent
Mammogram≥40yrs, microcalcifications, screeningLess sensitive in dense breasts, radiation
MRIHigh-risk screening, staging, problem-solvingExpensive, false positives, not routine

⚠️ Normal Imaging ≠ No Cancer: If clinical suspicion remains despite normal imaging, tissue diagnosis is still required. Always complete triple assessment.

Tissue Diagnosis (P3): Core biopsy preferred (histology + receptor status). FNA for cytology only. USS-guided. Results graded C1-C5 (cytology) or B1-B5 (histology).

•FNA (C grading): C1 inadequate, C2 benign, C3 atypia, C4 suspicious, C5 malignant
•Core Biopsy (B grading): B1 normal, B2 benign, B3 uncertain, B4 suspicious, B5 malignant
•Receptor Status: ER, PR, HER2 — guides treatment. Only from core biopsy, not FNA

✅ Triple Assessment Concordance: All three components must agree. If discordant, repeat biopsy or excision required. Never discharge on one reassuring result.

🔀 Breast Lump Algorithm

START: Discrete breast lump on examination
↓
❓ Does it meet 2-week wait criteria?
YES ↓NO ↓
Urgent 2-week wait referral to breast clinic
Routine referral for triple assessment
↓
Triple Assessment: Clinical + Imaging + Tissue Diagnosis

3️⃣ Key Differential Diagnoses

Distinguishing benign from malignant presentations

Benign (90%): Fibroadenoma (smooth, mobile, <35yrs), breast cyst (smooth, fluctuant, 35-50yrs), fat necrosis (history of trauma), lipoma (soft, mobile), abscess (red, hot, tender)

Malignant (10%): Invasive ductal carcinoma (hard, irregular, fixed — typically painless), invasive lobular carcinoma (diffuse thickening), inflammatory breast cancer (red, swollen, peau d'orange), Paget's disease (nipple eczema + underlying mass)

⚠️ Painless ≠ Safe: Most cancers are painless. A painless lump warrants the same rigorous assessment as a painful one.

Fibroadenoma and Cancer Risk: Simple fibroadenomas rarely transform directly into cancer (~0.002–0.125%). However, complex fibroadenomas (with cysts/sclerosing adenosis/atypia) carry ~3× higher subsequent breast cancer risk. Women with simple fibroadenoma and no family history do not have significantly increased risk.

Benign (90%): Atrophic vaginitis (most common), endometrial/cervical polyps, HRT-related bleeding, cervical ectropion, trauma

Malignant (10%): Endometrial cancer (5-10% of PMB), cervical cancer (rare if screened), vulval/vaginal cancer (very rare)

💊 Clinical Pearl: ALL postmenopausal bleeding requires urgent investigation (2-week wait) unless clearly HRT-related within first 6 months of starting. Even spotting counts.

Ovarian: Functional cyst (premenopausal, resolves), benign ovarian tumour, ovarian cancer (postmenopausal, solid/complex, ascites). Women ≥60 with abdominal swelling — think ovarian cancer first.

Uterine: Fibroids (firm, irregular uterus), pregnancy (always exclude!), endometrial cancer (postmenopausal)

Other: Bowel mass (constipation, diverticular), bladder distension (retention), ectopic pregnancy (acute pain, positive pregnancy test)

4️⃣ Common Conditions & Management

Evidence-based approaches to frequent presentations

🔴 Breast Lump

Discrete palpable mass in breast tissue

•Onset & Duration: When first noticed? Changing size? Discovered during self-exam?
•Characteristics: Size, location, painful vs painless — note: painless is MORE suspicious for cancer
•Associated Symptoms: Skin changes (dimpling, peau d'orange), nipple changes (inversion, discharge, eczema), axillary lumps
•Menstrual Relation: Cyclical changes? Worse premenstrually? Postmenopausal?
•Risk Factors: Age, family history (BRCA), previous breast disease, HRT use, nulliparity, late menopause

🛑 Painless = More Suspicious: Most breast cancers are painless. Do not be falsely reassured by absence of pain.

•Inspection: Asymmetry, skin changes (dimpling, peau d'orange), nipple inversion/retraction, erythema. Three positions: arms by side, raised, hands on hips
•Palpation: Size (cm), quadrant + clock position, consistency (soft/firm/hard), shape, mobility (mobile/tethered/fixed), tenderness
•Skin Tethering: Raise arms — does lump move with skin? Push towards chest wall — does skin dimple?
•Lymph Nodes: Axillary (5 groups), supraclavicular, infraclavicular. Document size, consistency, mobility

⚠️ Timing: Best examined days 7-14 of menstrual cycle. Avoid during menstruation (physiological nodularity).

•Imaging: USS <40yrs (first-line), mammogram ≥40yrs (first-line). Specialist decides modality. May use both if needed.
•Tissue Diagnosis: Core biopsy preferred (provides histology + receptor status) or FNA. USS-guided. Results in 1-2 weeks
•Triple Assessment: Clinical + Imaging + Tissue — all three must be concordant. If discordant, repeat or excision biopsy

Primary Care Role: Refer for triple assessment — do NOT arrange imaging yourself. Breast clinic coordinates all three components.

•Benign Lump (confirmed): Reassure. Teach self-examination. Safety-net: return if size/shape changes or new symptoms
•Simple Cyst: Aspiration if symptomatic. Clear fluid = benign. Bloodstained fluid = send for cytology. Recurrent cysts — reassure.
•Fibroadenoma: Conservative management if <3cm and confirmed benign. Excision if growing, >3cm, or patient preference. Simple fibroadenoma: malignant transformation rate only ~0.002–0.125%. Complex fibroadenoma: ~3× subsequent breast cancer risk — discuss surveillance.

💊 No drug treatment for benign lumps. Evening primrose oil, vitamin E, caffeine reduction — no evidence per NICE. Focus on reassurance and safety-netting.

🚩 Two-Week Wait Criteria (NICE NG12 2025)

🚩Age ≥30: Unexplained breast lump with or without pain (painless = MORE suspicious)
🚩Age ≥50: Unilateral nipple discharge (bloodstained or persistent clear)
🚩Any Age: Skin changes (peau d'orange, ulceration), nipple eczema (Paget's), new nipple inversion, axillary lump

Routine Referral: Age <30 with unexplained lump (unless high-risk family history). Bilateral nipple discharge. Recurrent breast abscess. Severe pain unresponsive to simple measures.

💢 Breast Pain (Mastalgia)

Cyclical or non-cyclical breast discomfort

•Cyclical vs Non-Cyclical: Worse premenstrually (cyclical, usually hormonal/benign) or constant (non-cyclical, needs examination)
•Location: Unilateral vs bilateral? Focal vs diffuse? Chest wall vs breast tissue?
•Severity: 0-10 scale. Impact on sleep, work, daily activities. Duration. Triggers (exercise, bra).
•Associated Symptoms: Lump? Discharge? Skin changes? Axillary pain?

✅ Reassurance: Breast pain alone (no lump, no skin changes) is cancer in <1% of cases. But always examine to exclude a discrete lump.

•Breast Examination: Exclude discrete lump (if present, manage as breast lump). Assess for diffuse nodularity (fibrocystic change — benign)
•Chest Wall Tenderness: Palpate ribs, costochondral junctions. Reproduce pain? → Musculoskeletal cause (costochondritis, Tietze syndrome)
•Skin Changes: Erythema (infection/inflammatory), peau d'orange (cancer), eczema (Paget's disease)

⚠️ Timing: If cyclical pain, examine mid-cycle (days 7-14) for clearer assessment.

•Reassurance: Breast pain alone is rarely cancer (<1%). Most resolve within 3-6 months. Cyclical pain often improves after menopause.
•Supportive Bra: Well-fitted, supportive bra day and night if severe. Sports bra for exercise.
•Topical NSAID (first-line for true mastalgia): Diclofenac sodium 1% gel (e.g. Voltarol Emulgel) applied TDS to affected area. Evidence specifically supports diclofenac gel for mastalgia — not ibuprofen gel.
•For musculoskeletal/chest wall pain: Paracetamol 1g QDS or ibuprofen 400mg TDS with food (short course).

💊 Prescribing (NICE CKS / BJGP):
1st line — Topical NSAID: Diclofenac 1% gel (Voltarol Emulgel), apply TDS to affected breast. Available OTC.
Oral analgesia (chest wall pain): Ibuprofen 400mg TDS with food or paracetamol 1g QDS.
2nd line (specialist only): Tamoxifen or danazol — do not initiate in primary care.
No evidence for: Evening primrose oil, caffeine reduction, vitamin E, pyridoxine (NICE).

⚠️ Hormonal Causes: Consider stopping/changing HRT or COCP if temporal relationship. Tamoxifen/danazol reserved for severe refractory cases (specialist only).

🚩 Refer if:

🚩Discrete lump found on examination
🚩Unilateral persistent pain >3 months with focal tenderness (exclude cancer)
🚩Severe pain unresponsive to simple measures, significantly affecting quality of life

✅ Safety-Netting: Return if pain worsens, becomes unilateral, or a lump develops. Review in 3 months if persistent.

🩸 Abnormal Vaginal Bleeding

Intermenstrual, postcoital, or postmenopausal bleeding

•Pattern: IMB (intermenstrual), PCB (postcoital), PMB (postmenopausal), HMB (heavy menstrual bleeding)
•Volume & Duration: Spotting vs heavy? Clots? Flooding? Pads/tampons per day?
•Menstrual History: LMP, cycle regularity, menopausal status, HRT use
•Associated Symptoms: Pain, discharge, dyspareunia, urinary symptoms, weight loss, bloating

🛑 PMB Definition: ANY vaginal bleeding >12 months after last menstrual period. Even spotting counts. Requires 2WW unless clearly HRT-related within first 6 months of starting.

•Speculum Examination: Identify bleeding source. Inspect cervix (ectropion, polyp, malignancy). Take cervical smear if due.
•Bimanual Examination: Uterine size (fibroids, pregnancy), adnexal masses, cervical excitation
•Vulval Inspection: Atrophic changes (PMB), lesions, trauma

🩺 Always offer chaperone. Document if declined. "I'm going to..." not "Can I...". Trauma-informed care is standard care.

•Pregnancy Test: ALWAYS in women of reproductive age
•Cervical Smear: If due (not diagnostic for cancer). Do NOT delay referral waiting for smear result
•STI Screen: If PCB or IMB with discharge/pelvic pain
•Pelvic USS: Transvaginal for endometrial thickness (PMB), fibroids, ovarian masses. Endometrial thickness >4mm postmenopausal = abnormal

Primary Care Role: For PMB, refer urgently (2WW) — do NOT arrange USS yourself. For IMB/PCB, consider USS if no obvious cause and not meeting 2WW criteria.

•Cervical Ectropion: Common cause of PCB. Benign. Reassure. Cautery if troublesome (specialist)
•Cervical Polyp: Visible on speculum. Refer for removal.
•Atrophic Vaginitis: Common cause of PMB. Treat with local vaginal oestrogen.

💊 Vaginal Oestrogen (NICE CKS 2024):
Estriol 0.1% cream (Ovestin): 1 applicator (0.5g) intravaginally nightly for 2-3 weeks, then twice weekly maintenance.
Estradiol 10mcg pessary (Vagifem/Vagirux): Once daily for 2 weeks, then twice weekly maintenance.
Both: minimal systemic absorption, no progestogen needed, safe long-term, safe in breast cancer survivors.

⚠️ HRT-Related Bleeding: Breakthrough bleeding common in first 3-6 months of continuous combined HRT. If persistent >6 months or heavy, refer for investigation.

🚩 Two-Week Wait Criteria

🚩Postmenopausal bleeding: ANY bleeding >12 months after last period (unless HRT-related within first 6 months)
🚩Visible cervical mass: On speculum examination

Routine Referral: Persistent IMB/PCB with no obvious cause. Recurrent cervical polyps. HMB unresponsive to medical management.

🔥 Pelvic Pain

Acute or chronic lower abdominal/pelvic pain

•Acute vs Chronic: Sudden onset <24hrs (exclude ectopic, torsion, appendicitis) vs >6 months (chronic)
•Location & Character: Unilateral vs bilateral, suprapubic vs iliac fossa, radiation (back, legs, rectum), severity 0-10
•Dyspareunia — Always Ask: Superficial (atrophy, infection, vaginismus, vulvodynia) vs deep (endometriosis, PID, fibroids, ovarian cysts). Most patients won't volunteer this.
•Associated Symptoms: Bleeding/discharge, urinary symptoms, bowel symptoms (IBS, constipation), fever

🛑 Red Flags: Sudden severe pain (ectopic, torsion, rupture), positive pregnancy test + pain (ectopic until proven otherwise), fever + pain (PID, appendicitis), peritonism (surgical abdomen), woman ≥60 with pelvic mass (ovarian cancer)

•Abdominal Examination: Inspection, palpation (tenderness, guarding, rebound, masses), percussion (ascites), auscultation
•Bimanual Examination: Cervical excitation (PID, ectopic), adnexal tenderness/masses, uterine tenderness
•Speculum Examination: Cervical discharge (PID), bleeding (ectopic, miscarriage)

⚠️ Acute Abdomen: If peritonism (guarding, rebound, rigidity), refer to A&E immediately.

•Pregnancy Test: ALWAYS in women of reproductive age. Positive + pain = ectopic until proven otherwise
•Urine Dipstick: Exclude UTI. MSU if positive.
•STI Screen: If sexually active, <25yrs, new partner, or discharge. Chlamydia/gonorrhoea NAAT.
•Pelvic USS: Transvaginal for ovarian cysts, masses, ectopic, fibroids. Urgent if acute pain + positive pregnancy test.

Chronic Pain: CA125 if >50yrs or postmenopausal with pelvic mass. Laparoscopy gold standard for endometriosis (specialist referral).

•Simple Analgesia: Paracetamol 1g QDS + ibuprofen 400mg TDS with food (if no contraindications)
•Endometriosis (medical management): COCP continuously (pill-running) to suppress menstruation. Alternatively progestogen-only: desogestrel 75mcg OD continuously. Refer to gynaecology for laparoscopy/specialist management.

💊 PID Prescribing (NICE CKS 2024 / BASHH):
Ceftriaxone 1g IM single dose STAT.
Plus Doxycycline 100mg BD orally for 14 days.
Plus Metronidazole 400mg BD orally for 14 days.
Contact tracing and partner notification essential. Avoid intercourse until treatment complete for both partners.

🚩 Urgent Referral/A&E

🚩Ectopic pregnancy: Positive pregnancy test + pain (urgent USS/gynaecology same day)
🚩Acute abdomen: Peritonism, severe pain, haemodynamic instability (A&E immediately)
🚩Ovarian torsion: Sudden severe unilateral pain, vomiting, adnexal mass (A&E — surgical emergency)

Routine Referral: Chronic pelvic pain >6 months unresponsive to simple measures. Suspected endometriosis. Persistent ovarian cysts >5cm or complex features on USS.

🌡️ Menopause & HRT: Comprehensive GP Guide

Based on NICE NG23 (updated November 2024), NICE CKS, and BMS Guidance 2024-2026

Clinical Diagnosis — No Tests Needed in Women >45 with Typical Symptoms

Menopause = no period for ≥12 months without another cause. Perimenopause = irregular cycles + symptoms. FSH NOT routinely required in women ≥45. In women 40-45: FSH may support diagnosis. Under 40: two elevated FSH readings (>40 IU/L) 4-6 weeks apart needed to diagnose POI.

⚠️ Perimenopause Masquerades as Depression

Any woman ~50 presenting with fatigue, low mood, brain fog, anxiety, or poor concentration: think perimenopause first. Women are frequently started on antidepressants for unrecognised perimenopause. HRT, not SSRIs, should be first-line for mood symptoms in perimenopausal women without prior depression history (NICE NG23 2024).

Full Symptom Spectrum (average duration 7 years; may persist for decades)

Vasomotor

  • • Hot flushes (sudden intense heat, flushing, sweating)
  • • Night sweats
  • • Palpitations
  • • Chills/cold sweats

Neuropsychiatric & Cognitive (often dominant presentation)

  • • Fatigue and low energy (reported by 95% of menopausal women)
  • • Brain fog / difficulty thinking clearly
  • • Poor memory and forgetfulness (94%)
  • • Difficulty concentrating (92%)
  • • Word-finding difficulty (90%)
  • • Irritability (93%)
  • • Anxiety (92%)
  • • Mood swings (90%)
  • • Low motivation (89%)
  • • Low mood / depression
  • • Panic attacks
  • • Low self-esteem and confidence

Sleep

  • • Insomnia / difficulty falling or staying asleep
  • • Sleep disruption (often secondary to night sweats but can be independent)

Urogenital / Sexual

  • • Vaginal dryness and soreness
  • • Dyspareunia (superficial = atrophy; always ask, rarely volunteered)
  • • Loss of libido (most severely experienced symptom)
  • • Recurrent UTIs / cystitis symptoms
  • • Urinary urgency or frequency
  • • Stress incontinence

Musculoskeletal

  • • Joint and muscle pains (arthralgia/myalgia)
  • • Reduced muscle strength

Skin, Hair, Other

  • • Dry skin, hair thinning, nail changes
  • • Dry eyes and mouth; burning mouth syndrome
  • • Formication (crawling/tingling skin sensation)
  • • Headaches and migraines (worsened by oestrogen fluctuation)
  • • Dizziness
  • • Weight gain / change in body composition
  • • Breast tenderness (especially perimenopause)
  • • Period irregularity / changes in menstrual pattern

The Single Most Important HRT Principle: Uterus Present or Not?

Clinical SituationHRT Type RequiredRationale
Uterus presentCombined HRT (oestrogen + progestogen)Oestrogen alone causes endometrial hyperplasia and cancer
No uterus (hysterectomy)Oestrogen-only HRTNo endometrium to protect; adding progestogen increases breast cancer risk unnecessarily
Subtotal hysterectomySeek specialist adviceCervical stump may have residual endometrium

Sequential vs Continuous Combined (Women WITH a Uterus)

RegimenIndicationType / Bleed
Sequential combined HRTPerimenopausal (last period <12 months ago)Oestrogen daily + progestogen 10-14 days/cycle → monthly withdrawal bleed
Continuous combined HRTPost-menopausal (no period ≥12 months)Oestrogen + progestogen every day → no bleed (after initial 3-6 months)

Important: If post-menopausal but started on sequential HRT, switch to continuous combined after 1 year amenorrhoea (or by age 54 if started sequential at 45+).

Oestrogen Preparations — Prefer Transdermal Route

Transdermal oestrogen does NOT carry the increased VTE or stroke risk associated with oral oestrogen.

PreparationBrand ExamplesStarting DoseUsual DoseRoute/Frequency
Estradiol patch (twice-weekly)Evorel®, Estradot®25-50 mcg/24h50 mcg/24hChange every 3-4 days
Estradiol patch (once-weekly)FemSeven®25-50 mcg/24h50 mcg/24hChange once weekly
Estradiol gelOestrogel®, Sandrena®1 pump (0.5mg) or 0.5mg sachet2 pumps or 1mg sachetApply daily to arm/thigh
Estradiol sprayLenzetto®1 spray (14 mcg)2-3 spraysApply daily to inner forearm
Oral estradiolProgynova®, Zumenon®1mg daily1-2mg dailyOral, once daily. Avoid if BMI ≥30 or VTE/CVD risk.

Titrating: Start low (e.g. Evorel 25 or 1 pump Oestrogel). Review at 3 months. Increase to standard dose (50mcg patch / 2 pumps) if symptoms persist. Maximum: 100mcg patch / 4 pumps (seek specialist advice above standard doses).

Progestogen Preparations (Women WITH a Uterus) — Prefer Micronised Progesterone

PreparationBrandSequential DoseContinuous Dose
Micronised progesterone ★ PREFERREDUtrogestan®, Gepretix®200mg orally at bedtime for 14 days/cycle100mg orally at bedtime daily
Medroxyprogesterone acetateProvera®10mg for 12-14 days/cycle2.5-5mg daily
Norethisterone—700mcg-1mg for 12-14 days500mcg-1mg daily
LNG-IUS 52mg ★ UNDERUSEDMirena®, Benilexa®, Levosert®Suitable at any stageLocal progestogen; change every 5 years

★ Why Utrogestan? Body-identical, plant-derived, significantly more favourable breast cancer risk profile than synthetic progestogens. Best choice for most women.

★ Mirena IUS: Excellent underused option — delivers progestogen locally with minimal systemic absorption. Also provides contraception. Only 52mg devices (Mirena®, Benilexa®, Levosert®) licensed for HRT; Kyleena® (19.5mg) is NOT sufficient.

Utrogestan dose adjustment: If oestrogen >50mcg patch / >2 pumps Oestrogel, increase Utrogestan to 200mg nightly continuous (seek specialist advice).

Pre-made Combined Preparations

BrandOestrogenProgestogenType
Femoston 1/10, 2/10Estradiol 1mg or 2mgDydrogesterone 10mg (14 days)Sequential
Femoston-conti 0.5/2.5, 1/5Estradiol 0.5-1mgDydrogesterone 2.5-5mgContinuous
Elleste Duet 1mg, 2mgEstradiolNorethisterone 1mg (12 days)Sequential
Elleste Duet ContiEstradiol 2mgNorethisterone 1mgContinuous
Evorel Sequi®50 mcg estradiol patchNorethisterone 170 mcg/d (14 days)Sequential patch
Evorel Conti®50 mcg estradiol patchNorethisterone 170 mcg/dContinuous patch
Kliovance / KliofemEstradiol 1-2mgNorethisterone 0.5-1mgContinuous
Tibolone (Livial®)Synthetic (oestrogenic + progestogenic + androgenic)—Post-menopausal only; avoid in breast cancer history

Vaginal / Local Oestrogen (Genitourinary Syndrome of Menopause — GSM)

All women with GSM symptoms should be offered local vaginal oestrogen regardless of whether they are taking systemic HRT. Safe for long-term use. Also safe in breast cancer survivors (discuss with oncologist if ER+ cancer on aromatase inhibitors).

PreparationBrandDoseFrequency
Estriol 0.1% creamOvestin®0.5g (500 mcg)Daily for 2-3 weeks, then twice weekly
Estradiol vaginal tabletVagifem®, Vagirux®10 mcgDaily for 2 weeks, then twice weekly
Estradiol vaginal ringEstring®7.5 mcg/dayChange every 3 months
Prasterone / DHEAIntrarosa®6.5mgDaily intravaginally; safe post-breast cancer

Starting HRT: Practical Notes

• Review at 3 months after starting: assess symptom response, side effects, and unscheduled bleeding

• Unscheduled bleeding in first 3 months: common, can reassure if settling

• Bleeding after 3 months: investigate (TVUS and/or endometrial biopsy / referral)

• Annual review thereafter: reappraise benefits and risks, check BP, BMI

• Allow at least 3 months before changing regime — side effects often settle

• NICE advises brand prescribing for HRT to aid product identification

• Transdermal preferred if BMI >30, personal/family history of VTE, thrombophilia, migraine with aura, hypertension

All risks below are per 1,000 women over 5 years (NICE NG23 Discussion Aid, November 2024)

How to say it: "If I take 1,000 women aged 50 and follow them for 5 years — some will get breast cancer whether they take HRT or not. We're talking about a small number of EXTRA cases on top of what would happen anyway."

RiskBackground (No HRT)Combined HRT (synthetic progestogen)Oestrogen-Only HRTCombined HRT (micronised progesterone)
Breast cancer~23/1,000 aged 50-59 over 5 years+4 extra cases−4 (slightly protective)Likely neutral / ~RR 1.00
Endometrial cancerLowContinuous: REDUCES risk; Sequential long-term: may slightly increaseSubstantially increased if uterus present (why combined HRT is mandatory)—
Ovarian cancerVery low+1 extra case/1,000 over 5 years (small absolute risk)+1 extra case/1,000 over 5 years—
Cervical cancer—Not increased; possibly slightly protective (squamous). HPV-driven, not oestrogen-driven.Not increased—
VTE / DVT~1/1,000/yearOral: ~2-3× background riskTransdermal: NO significantly increased risk—
Coronary heart disease—If started within 10 years of menopause / under 60: neutral to beneficial (reduces CHD events)If started >10 years after menopause: no benefit; potential harm—
Stroke—Oral: small increase. Transdermal: no significant increase——
Osteoporosis / Fractures—Reduces any fracture by 28%; major osteoporotic fracture by 40%; hip fracture by 34%Same benefitSame benefit
Life expectancy—NICE (2024): overall, taking HRT is unlikely to affect life expectancy in women ≥45. Reflects balance of small cancer risks vs CVD, bone, and wellbeing benefits.

⚠️ Breast Cancer Key Points

  • • Risk INCREASES with duration of use — 10 years combined adds ~2.6% absolute risk
  • • Risk HIGHER with current use vs. past use
  • • Risk DECLINES after stopping HRT but persists ≥10 years
  • • Choice of progestogen matters: micronised progesterone (Utrogestan®) carries the lowest breast cancer risk
  • • Lifestyle factors (obesity, alcohol) may have comparable or greater impact than HRT
  • • Oestrogen-only HRT: little or no increase — possibly slight reduction

✅ The "Timing Hypothesis" (CVD)

HRT is beneficial for CHD when started within 10 years of menopause or under age 60 ("window of opportunity"). Starting HRT >10 years after menopause or over 60 provides no cardiovascular benefit and may cause harm. NICE states HRT should NOT be used for primary or secondary CVD prevention, but transdermal HRT can be considered for symptomatic women with well-controlled CVD risk after specialist review.

Duration of HRT — No Arbitrary 5-Year Limit

  • • NICE: no arbitrary time limits on HRT use — duration based on individual annual risk-benefit assessment
  • • HRT for 5 years in women under 60 does not confer significant additional risks
  • • Menopausal symptoms last an average of 7 years and may persist for decades
  • • Women should NOT be told they MUST stop at 5 years — this is not evidence-based
  • • Bone protection is lost when HRT is stopped
  • • If symptoms return after stopping, restarting is appropriate after discussion
  • • Use lowest effective dose for long-term use; review annually

HRT is first-line and most effective (reduces vasomotor symptoms by up to 90%). The options below are for women who cannot or do not wish to take HRT.

🆕 Fezolinetant (Veoza®) — NICE-Approved March 2026

  • • Mechanism: NK3 receptor antagonist — blocks hypothalamic neurokinin B pathway responsible for triggering hot flushes. Does NOT alter hormone levels.
  • • Dose: 45mg tablet, once daily
  • • Efficacy: Reduces hot flush frequency by ~60% vs 45% with placebo at 12 weeks
  • • NICE: Recommended for moderate-to-severe vasomotor symptoms when HRT is medically unsuitable or not desired
  • • Suitable when HRT contraindicated e.g. DVT, PE, some cases of diabetes or heart disease after clinical risk assessment
  • • Monitoring: LFTs before and during treatment (hepatotoxicity signal in trials)
  • • Not yet recommended alongside HRT — indicated as alternative, not adjunct

SSRIs / SNRIs for Vasomotor Symptoms

DrugStarting DoseTarget DoseNotes
Venlafaxine (SNRI)37.5mg daily for 1 week75mg dailyMost evidence; reduces hot flushes by 40-60%; monitor BP. SAFE with tamoxifen.
Paroxetine ⚠️10mg daily20mg dailyDO NOT use with tamoxifen (inhibits CYP2D6 — reduces tamoxifen to inactive form)
Fluoxetine ⚠️20mg daily20mg dailyDO NOT use with tamoxifen (CYP2D6 inhibitor)
Escitalopram / Citalopram10mg daily10-20mg dailySome evidence; safer with tamoxifen. Citalopram: off-label for vasomotor symptoms.

NICE advises against offering paroxetine or fluoxetine to women on tamoxifen. SSRI benefit for flushes often seen within 2 weeks. These are off-label for vasomotor symptoms.

Gabapentin

  • • Dose: 300mg nocte, increasing to 300mg TDS (maximum for hot flushes)
  • • Reduces hot flush frequency by ~45-54% vs placebo
  • • Side effects: dizziness, sedation (worse at initiation, improves by week 4)
  • • Schedule 3 controlled drug — limited prescribing; use with caution
  • • Pregabalin 75-150mg BD also has evidence

Clonidine

  • • Alpha-2 agonist; modest benefit for flushes (weaker evidence than SNRIs or gabapentin)
  • • Starting dose: 50 micrograms BD, increasing to 75 micrograms BD
  • • Licensed for menopausal flushing; most useful in women taking tamoxifen
  • • Side effects: dry mouth, sedation, dizziness. Do not stop abruptly — rebound hypertension risk

CBT (Cognitive Behavioural Therapy)

NICE (NG23 2024) recommends menopause-specific CBT as an option for vasomotor symptoms, sleep disturbance, and depressive symptoms — as adjunct to HRT or when HRT is contraindicated/not wanted.

⚠️ SSRIs for Mood vs Vasomotor Symptoms — KEY Clinical Point

  • • For perimenopausal low mood without prior depression history: HRT is first-line, not SSRIs. Oestrogen deficiency is often the primary driver.
  • • If mood persists despite adequate HRT: then consider adding SSRIs/SNRIs
  • • Established depressive illness predating menopause: SSRIs are appropriate
  • • Key message: Many women prescribed SSRIs actually have perimenopause-related mood change. A 3-month HRT trial is often more appropriate and more effective.

❌ Why "Natural" Alternatives Don't Work (and May Be Unsafe)

Wild yam creams / "natural progesterone": Wild yam (Dioscorea) contains diosgenin. The human body cannot convert diosgenin into progesterone — this requires a pharmaceutical lab. Wild yam creams do NOT raise serum progesterone levels meaningfully and provide NO endometrial protection for women taking oestrogen — a potentially dangerous misconception.

Phytoestrogen-rich foods / "HRT bread": Soya isoflavones show modest hot flush reduction (~20-25%) but results are heterogeneous and quality is poor. Effect size is significantly weaker than pharmaceutical HRT (which reduces flushes by up to 90%). No bone, CVD, or cognitive benefit. Unregulated — dose and bioavailability are highly variable.

Compounded bioidentical hormones (private): Not regulated or quality-assured. May contain DHEA, pregnenolone, or unapproved hormones. No evidence of superiority over regulated body-identical HRT (Utrogestan®, Oestrogel®). Risk of inappropriate dosing, contamination, and lack of endometrial protection.

"The HRT we prescribe on the NHS — oestrogen gel and Utrogestan capsules — IS made from plant sources, processed properly so your body can actually use it. You get the 'natural' hormone, but in a form that actually works."

Testosterone in Menopause: When, Why, and How

When to consider (NICE NG23): Hypoactive sexual desire disorder (HSDD) / low libido in menopause, AFTER:

  • • A trial of conventional HRT for at least 3–6 months
  • • Oestrogen dose has been optimised (including vaginal oestrogen if applicable)
  • • Relationship issues, sexual pain, mental health, and medication side effects (e.g. SSRIs) excluded

Testosterone is NOT a standard third component of HRT — prescribing it routinely at initiation is not supported by BMS or NICE.

Emerging evidence also for: improved mood, cognitive function, energy, concentration, and "brain fog" when oestrogen alone is insufficient.

Route, Dose, and Monitoring

Route: Transdermal gel is standard. Available preparations (all off-licence for women — document in notes): AndroFeme® 1%, Testogel®, Tostran®.

Dose: Female physiological dose (~5mg/day), approximately one-tenth of the male dose.

Target: Upper end of normal female range — NOT male range. Supraphysiological levels cause side effects.

Monitoring:

  • • Baseline total testosterone before starting (ensure not already at upper end of female range)
  • • Recheck at 6–12 weeks after starting
  • • Then every 6–12 months
  • • Annual review of ongoing benefit vs. risk

Side effects at supraphysiological doses: acne, hirsutism, irreversible voice changes, clitoromegaly — avoid excessive dosing.

No long-term safety data for cardiovascular outcomes or breast cancer in women (unlike oestrogen).

⚠️ Key Clinical Tip: Try Switching Route Before Adding Testosterone

Oral oestrogens elevate SHBG, reducing free testosterone. Women with persistent low libido on oral oestrogen may improve simply by switching to transdermal oestrogen — which does not raise SHBG — without needing to add testosterone. Always try this first.

Definitions

• Premature Ovarian Insufficiency (POI): Menopause before age 40 — affects ~1% of women

• Early menopause: Menopause aged 40–44

• Surgical menopause: Bilateral oophorectomy at any age

Why POI Is Different — It Is an Endocrine Deficiency State

POI is fundamentally different from natural menopause — it is an endocrine deficiency state, not a natural ageing process. Untreated POI causes:

  • • Significantly increased risk of CVD, osteoporosis, and cognitive impairment
  • • Reduced life expectancy
  • • Increased risk of anxiety, depression, and autoimmune diseases

Standard menopause HRT risk considerations do not apply to POI. HRT in POI is hormone replacement — replacing what is missing, not adding extra hormones.

Diagnosis

Two elevated FSH readings (>40 IU/L) taken 4–6 weeks apart in a woman under 40. Refer all confirmed POI to a menopause specialist.

Management: NICE and BMS — HRT Until at Least Age 51

ALL women with POI or early menopause should take HRT (or COCP) until at least age 51 — even if asymptomatic — to protect cardiovascular, bone, and cognitive health.

Key differences from managing natural menopause:

  • • Higher oestrogen doses often needed — use physiological replacement doses; step up to 100mcg patch / 4 pumps Oestrogel if required
  • • COCP is an alternative and provides contraception. POI does NOT reliably prevent pregnancy — ~5–10% conceive spontaneously
  • • HRT may be preferable to COCP for bone health and cardiovascular markers
  • • After reaching age 51, reassess need for ongoing HRT (many will benefit from continuing)
  • • Testosterone may be considered if low libido or cognitive symptoms persist despite adequate HRT

⚠️ A Clinically Underrecognised Risk: Earlier Ovarian Failure After Hysterectomy

Hysterectomy with ovarian preservation is associated with a ~2-fold increased risk of ovarian failure compared to women with intact uteri (HR 1.92).

After 4 years follow-up: 14.8% of hysterectomy patients had experienced ovarian failure vs 8.0% controls.

After 5 years: 20.6% of hysterectomy patients had reached menopause.

Risk is greatest with unilateral oophorectomy (HR 2.93) and in women under 40. Even women retaining both ovaries have significantly increased risk (HR 1.74).

The "5-year figure" commonly cited is an approximation — the data shows accelerated ovarian decline over time rather than a defined endpoint.

HRT Choice After Hysterectomy

• Oestrogen-only HRT — no progestogen needed (no uterus to protect)

• Oestrogen-only HRT is associated with no increased breast cancer risk and possibly a slight reduction — this is an important reassurance for patients

• Exception: subtotal hysterectomy — cervical stump may have residual endometrium; seek specialist advice before prescribing oestrogen-only

• If hysterectomy occurred before natural menopause, treat as for early menopause: continue HRT until at least age 51, then reassess

✅ Clinical Approach in Practice

• Counsel women at the time of hysterectomy: they may experience earlier menopause than expected

• If a woman in her mid-to-late 40s had a hysterectomy years ago and presents with symptoms of oestrogen deficiency — check FSH

• Don't wait for typical menopausal age to consider HRT in this group

• Transdermal oestrogen preferred (as for all HRT) — no VTE risk, suitable even with BMI >30

🛑 HRT After Breast Cancer — Specialist Area: Refer

• NICE: do not routinely offer systemic HRT to women with a history of breast cancer

• HRT is absolutely contraindicated in women with active breast cancer receiving treatment

• In exceptional cases with severe debilitating symptoms (e.g. surgical menopause post-breast cancer treatment), HRT may be considered after thorough risk-benefit discussion with a menopause specialist

• Vaginal oestrogen (low dose, minimally absorbed) is generally safer — discuss with the patient's oncologist; growing evidence supports its use even in breast cancer survivors. Prasterone / DHEA (Intrarosa®) is also an option.

Tamoxifen Duration — 10 Years Is Now Standard of Care

The landmark ATLAS and aTTom trials (2012–2013) showed that 10 years of tamoxifen is superior to 5 years for ER+ early breast cancer:

  • • Additional 25% reduction in recurrence from year 10 onwards
  • • Additional ~30% reduction in breast cancer mortality from year 10
  • • Benefits emerge mainly after the 7–10 year mark — there is a "carryover effect" from 5 years but additional benefit accrues later

Current guidance: For premenopausal women and those who become peri/post-menopausal on tamoxifen, 10 years is now standard of care for higher-risk ER+ early breast cancer.

Postmenopausal women after 5 years of tamoxifen may switch to aromatase inhibitors for the extended period.

⚠️ Critical Drug Interaction: Tamoxifen + Paroxetine / Fluoxetine

Paroxetine and fluoxetine are potent CYP2D6 inhibitors and must NOT be co-prescribed with tamoxifen — they reduce its conversion to the active metabolite endoxifen, significantly reducing its efficacy. Use venlafaxine, citalopram, or escitalopram instead for hot flushes or mood symptoms in women on tamoxifen.

Other Drugs Used in Menopause Management

DrugIndicationNotes
Tibolone (Livial®)Post-menopausal women >1 year after LMPSynthetic steroid with oestrogenic, progestogenic, and androgenic activity; benefits libido; avoid in breast cancer history; slightly higher stroke risk than transdermal HRT
Bisphosphonates (alendronate, risedronate)Osteoporosis when HRT not appropriateFirst-line pharmacological treatment for established osteoporosis
DenosumabOsteoporosis (specialist initiated)Monoclonal antibody; rebound fracture risk on stopping — do not discontinue without plan
Vitamin D + CalciumOsteoporosis prevention — all post-menopausal womenEspecially if housebound or low dietary intake
OspemifeneGSM — oral SERMLicensed for moderate-severe GSM; useful if local vaginal application not acceptable
Prasterone / DHEA (Intrarosa®)GSMIntravaginal; converted locally to both oestrogens and androgens; safe post-breast cancer (discuss with oncologist)

Practical Phrases for Discussing HRT with Patients

On Starting HRT:

"The evidence is reassuring for most women — the benefits of taking HRT outweigh the risks. The old fears were largely based on studies of older women taking high-dose oral hormones, which is very different from what we prescribe now."

On Breast Cancer Risk:

"Out of 1,000 women in their 50s taking combined HRT for 5 years, we'd expect about 4 extra cases of breast cancer. To put that in context — being overweight adds about the same risk. And if we use the safest type of progesterone (Utrogestan), the breast cancer risk appears to be even lower."

On Oestrogen-Only HRT (post-hysterectomy):

"Because you've had a hysterectomy, you can take oestrogen alone, which is actually associated with NO increased breast cancer risk — and possibly even a slight reduction."

On Duration:

"There's no magic cut-off at 5 years. NICE is clear — you can continue as long as the benefits outweigh the risks for you as an individual. We'll review it together every year."

On Transdermal Route:

"Using HRT through the skin — patch, gel, or spray — is much safer than tablets, particularly for your blood vessels. It doesn't increase the risk of blood clots, unlike some tablets."

On Wild Yam / Natural Alternatives:

"Wild yam cream sounds natural but your body simply can't turn the yam chemicals into actual progesterone without a lab doing it first. So it can't protect your womb lining. The HRT I'm prescribing is itself made from plant sources — it's 'natural' in that sense — but processed properly so your body can actually use it."

On Stopping:

"If you stop HRT, symptoms can return — not because HRT was masking your menopause, but because your menopause was still going on. Some women's symptoms last for decades. Restarting is always an option."

Things GPs Should Know That Are Often Missed

Contraception and HRT: HRT is NOT a contraceptive. Continue contraception for 1 year after last period if over 50, 2 years if under 50. The Mirena 52mg IUS provides both endometrial protection AND contraception — an excellent dual-purpose option in perimenopause.

Dementia: Some evidence suggests HRT may reduce dementia risk when started early in the menopausal transition (the "timing hypothesis"), but this is not yet sufficient to recommend HRT for dementia prevention (NICE 2024). Ongoing research (COGNATE trial) investigating this.

GSM can present years after menopause: Vaginal dryness, recurrent UTIs, urinary urgency may present well after other symptoms have resolved — sometimes years later. Often misdiagnosed as recurrent infection. Low-dose vaginal oestrogen is highly effective and safe for indefinite use.

Route of oestrogen affects testosterone efficacy: Women with persistent HSDD on oral oestrogen may improve simply by switching to transdermal oestrogen — oral oestrogen increases SHBG, reducing free testosterone. Try this before adding testosterone.

Unscheduled Bleeding Protocol: First 3 months = common, reassure if settling. After 3 months = TVUS +/- endometrial biopsy; urgent referral if post-menopausal bleeding. Women on long-term sequential HRT (>5 years): consider moving to continuous combined (or Mirena) by age 54 to reduce endometrial risk.

Annual BP Check: All women on HRT should have blood pressure checked at least annually, especially those on oral preparations.

High-dose oestrogen in POI: Standard doses may be insufficient for young women with POI. Step-wise escalation to maximum 100mcg patch / 4 pumps Oestrogel at 3-monthly intervals is acceptable and evidence-supported.

Routine Referral to Menopause Specialist

•

Premature Ovarian Insufficiency (menopause <40yrs) — needs specialist assessment, higher-dose HRT, fertility discussion

•

Complex HRT needs e.g. previous breast cancer, VTE, severe liver disease, subtotal hysterectomy

•

Persistent symptoms despite adequate HRT trial (check compliance, dose, consider testosterone)

•

Testosterone initiation — most GPs refer to menopause specialist for first prescription

•

Unscheduled bleeding persisting beyond 3-6 months on HRT

✅ Most Women Managed in Primary Care: Uncomplicated menopause with typical symptoms. Standard HRT regimens (oestrogen + Utrogestan or Mirena IUS). Vaginal oestrogen for genitourinary symptoms. Annual review and adjustment. Find accredited menopause clinics at: thebms.org.uk

5️⃣ Red Flags & Must-Not-Miss Diagnoses

Critical warning signs requiring urgent action

🚩 Breast Cancer Red Flags

🚩

Hard, irregular, fixed breast lump — especially if painless. Most breast cancers are painless. A pain-free lump is MORE suspicious. Refer 2WW if age ≥30 with unexplained lump.

🚩

Skin changes: Peau d'orange, skin tethering, ulceration, erythema (inflammatory breast cancer)

🚩

Nipple changes: New inversion/retraction, eczema-like rash (Paget's disease), bloodstained discharge (especially unilateral, single duct)

🚩

Axillary lymphadenopathy: Hard, fixed, non-tender lymph nodes. May be first presentation of breast cancer.

🚩 Gynaecological Cancer Red Flags

🚩

Postmenopausal bleeding: ANY vaginal bleeding >12 months after last period. 5-10% have endometrial cancer. Refer 2WW (unless clearly HRT-related within first 6 months).

🚩

Visible cervical mass: On speculum examination. Refer 2WW for suspected cervical cancer.

🚩

Ovarian cancer triad: Persistent bloating + early satiety + pelvic/abdominal pain (>12 times/month). Check CA125. Pelvic mass = urgent USS.

🚩

Woman ≥60 with abdominal swelling or "getting fatter": Do not attribute to weight gain — investigate for ovarian cancer (CA125 + pelvic USS). One of the most commonly missed presentations in primary care.

🚩

Unexplained weight loss: >5% body weight in 6 months + gynaecological symptoms. Consider endometrial or ovarian cancer.

⚡ Acute Gynaecological Emergencies

⚡

Ectopic pregnancy: Positive pregnancy test + pelvic pain/bleeding. Urgent same-day gynaecology referral or A&E if haemodynamically unstable.

⚡

Ovarian torsion: Sudden severe unilateral pelvic pain, vomiting, adnexal mass. Surgical emergency. Refer A&E immediately.

⚡

Ruptured ovarian cyst: Sudden severe pain, peritonism, haemodynamic instability. Refer A&E.

⚡

Severe PID: Fever >38°C, severe lower abdominal pain, peritonism, vomiting. Risk of tubo-ovarian abscess. Admit for IV antibiotics.

6️⃣ Referral Pathways & Safety-Netting

When to refer and how to safety-net effectively

Referral Criteria & Pathways

NICE NG12 (2025) two-week wait and routine referral criteria

🚩 Breast Cancer 2WW (NICE NG12 2025)

•Age ≥30: Unexplained breast lump with or without pain (painless = MORE suspicious)
•Age ≥50: Unilateral nipple discharge (bloodstained or persistent clear)
•Any age: Skin changes (peau d'orange, ulceration), nipple eczema (Paget's), new nipple inversion, unexplained axillary lump

🚩 Gynaecological Cancer 2WW

•Postmenopausal bleeding: ANY vaginal bleeding >12 months after last period (unless HRT-related within first 6 months)
•Visible cervical mass on speculum examination
•Pelvic mass palpable on examination (not obviously fibroids) + CA125 elevated (use age-adjusted thresholds)

Breast Routine Referral

•Age <30 with unexplained lump (unless high-risk family history → 2WW)
•Bilateral nipple discharge (usually benign but needs assessment)
•Recurrent breast abscess (exclude underlying malignancy)
•Severe breast pain unresponsive to simple measures

Gynaecology Routine Referral

•Persistent IMB/PCB with no obvious cause on examination
•HMB unresponsive to medical management
•Chronic pelvic pain >6 months unresponsive to simple measures
•Suspected endometriosis (for laparoscopy and specialist management)
•Persistent ovarian cysts >5cm or complex features on USS

✅ Effective Safety-Netting Framework

1. Explain What to Watch For:

"Return if the lump gets bigger, skin changes, or nipple discharge develops."

2. Give Specific Timeframes:

"If symptoms haven't improved in 2 weeks, or worsen at any time, come back sooner."

3. Empower Patient Action:

"You know your body best. If you're worried, don't wait — we'd rather see you again than miss something important."

4. Document Clearly:

Record safety-netting advice given, red flags explained, and follow-up plan. Use Read codes for audit trail.

⚠️ Common Failures: Vague advice ("come back if worse"), no timeframe given, not documenting advice. Be specific, give deadlines, document everything.

7️⃣ Communication Skills & Sensitive Consultations

Navigating difficult conversations with empathy and clarity

Key Communication Scenarios

Practical scripts and frameworks for challenging consultations

SPIKES Framework for Breaking Bad News

S - Setting: Private room, sit down, turn off phone, offer chaperone/relative

P - Perception: "What have you been told so far?" "What are you expecting today?"

I - Invitation: "Would you like me to explain the results?"

K - Knowledge: Warning shot: "I'm afraid the results show something concerning." Then give information in chunks

E - Empathy: Acknowledge emotion: "I can see this is very difficult news." Silence is OK.

S - Strategy: "The specialist will discuss treatment options. I'll be here to support you throughout."

💬 Example Script: Urgent Breast Referral

"I've examined the lump you found, and I think it needs specialist assessment. I'm arranging an urgent appointment at the breast clinic within two weeks. This doesn't mean you have cancer — in fact, most people we refer don't — but it's important we check thoroughly. The clinic will do scans and possibly a biopsy to find out exactly what it is. How are you feeling about that?"

✅ Shared Decision Making for HRT

1. Explore Patient's Agenda: "What matters most to you — stopping the hot flushes, improving sleep, or something else?"

2. Present Options: "We have HRT (most effective), fezolinetant (new non-hormonal tablet), SSRIs/venlafaxine, or lifestyle changes."

3. Discuss Risks/Benefits: "HRT increases breast cancer risk slightly — about 4 extra cases per 1,000 women over 5 years. The type of progesterone matters — Utrogestan appears much safer than synthetic types."

4. Check Understanding: "What are your thoughts? What would help you decide?"

5. Support Decision: "There's no rush. We can try one approach and change if it doesn't suit you."

⚠️ Avoid Paternalism: Don't say "You should take HRT" or "I wouldn't worry about the risks." Present information neutrally, respect patient autonomy.

🩺 Trauma-Informed Pelvic Examination

Before: "I'd like to examine you internally. This involves using a speculum and feeling inside. You can stop at any time. Would you like a chaperone present?"

During: Explain each step before doing it. Use "I'm going to..." not "Can I...". Narrate: "I'm just inserting the speculum now. You might feel some pressure." Check in: "Are you OK?"

After: "That's all done. You can get dressed now. Take your time." Debrief clearly.

🛑 Never Assume Consent

Previous examination ≠ consent for this one. Document if examination declined (use "patient declined" not "refused"). Consider trauma history. Offer female clinician if available.

8️⃣ Prevention & Screening

National screening programmes and risk reduction strategies

•NHS Breast Screening: Women 50-71 invited every 3 years. Mammogram (2 views). UK 10-year breast cancer survival ~77% overall; nearly 100% if caught at stage 1 — screening is effective.
•High-Risk Women: BRCA1/2, strong family history — annual MRI from age 30/40. Refer to genetics/familial breast cancer service.
•Breast Awareness: Encourage women to know what's normal for them. Report any new lump, skin change, or nipple change promptly regardless of screening date.
•NHS Cervical Screening (England): 25-49yrs: every 3 years. 50-64yrs: every 5 years. HPV primary testing since 2019.
•HPV Vaccination: Gardasil-9 now covers 9 HPV strains. Routine: girls + boys aged 12-13. Catch-up to age 25.
•HRT and Cervical Cancer: HRT does not increase overall cervical cancer risk. Standard cervical screening should continue regardless of HRT use.

No national ovarian cancer screening programme in the UK. Previous trials (UKCTOCS) did not show screening reduced ovarian cancer mortality.

•Symptomatic Detection: Only realistic strategy. The classic triad (bloating, early satiety, pelvic/abdominal pain >12 times/month) should trigger CA125 + pelvic USS.
•CA125 Age-Adjusted Thresholds (proposed 2026): <50yrs use >35 U/mL; ≥50yrs use >70 U/mL to reduce false positives in younger women.
•High-Risk: BRCA1/2, Lynch syndrome, strong family history — refer for genetic counselling and discuss prophylactic surgery options.
•Modifiable Breast Cancer Risk: Alcohol (one of the biggest modifiable risks — each unit/day increases risk by ~7%), obesity (especially postmenopausal), physical inactivity, prolonged HRT (small but real), smoking
•Protective Factors: Breastfeeding (each year reduces risk ~4.3%), physical activity, healthy weight, early first pregnancy
•Osteoporosis Prevention: HRT highly effective — 28-40% fracture risk reduction. Vitamin D + calcium for all post-menopausal women. Weight-bearing exercise. Bisphosphonates when HRT not appropriate.

9️⃣ MDT Working & Specialist Services

Collaborative care and when to involve specialists

•Breast Surgeon: Triple assessment, biopsy, excision, mastectomy/lumpectomy decisions
•Radiologist: Imaging interpretation, biopsy guidance, staging
•Pathologist: Tissue diagnosis, receptor status, grading
•Oncologist: Chemotherapy, radiotherapy, endocrine therapy (tamoxifen, aromatase inhibitors), HER2 therapy
•Breast Care Nurse: Key contact for patient — coordinates care, emotional support, information provision
•Gynaecological Oncologist: Endometrial, ovarian, cervical cancer surgery and management
•Menopause Specialist: Complex HRT, POI, testosterone, post-breast cancer menopause, persistent symptoms
•Urogynaecologist: Pelvic organ prolapse, urinary incontinence, complex pelvic floor issues
•Gynaecologist: Endometriosis, fibroids, laparoscopy, hysteroscopy, fertility assessment
•Geneticist: BRCA testing, Lynch syndrome, familial cancer risk counselling
•Cancer Support: Emotional support, community Macmillan/Maggie's Centre, survivorship reviews, late effects monitoring
•Prescribing Support: Shared-care HRT prescribing, ongoing monitoring, dose adjustments in line with specialist recommendations
•Annual HRT Review: BP, BMI, unscheduled bleeding, symptom control, risk reassessment
•Bone Health: DEXA scanning (if indicated), bisphosphonates or vitamin D prescribing after specialist initiation
•Patient Advocacy: Navigating referral pathways, ensuring timely specialist access, addressing health inequalities

🎓 MRCGP Exam Focus

AKT must-knows and SCA hot topics

🎯 Breast & Gynaecology AKT Must-Knows

🚩 2WW Criteria

  • • Breast lump ≥30yrs (with OR without pain)
  • • Unilateral nipple discharge ≥50yrs (bloodstained or persistent clear)
  • • Skin changes, nipple eczema (Paget's), new nipple inversion
  • • Postmenopausal bleeding (unless HRT-related)
  • • Visible cervical mass on speculum
  • • Pelvic mass + elevated CA125

💊 Drug Facts

  • • Diclofenac 1% gel (NOT ibuprofen gel) for mastalgia
  • • PID: ceftriaxone 1g IM + doxycycline 100mg BD + metronidazole 400mg BD × 14 days
  • • Fezolinetant (Veoza) 45mg OD: new NICE-approved (March 2026) non-HRT option for vasomotor symptoms
  • • Paroxetine + fluoxetine: DO NOT co-prescribe with tamoxifen (CYP2D6 inhibitors)
  • • Venlafaxine 75mg OD: best-evidence SNRI for hot flushes
  • • Utrogestan: preferred progestogen — body-identical, lowest breast cancer risk
  • • Mirena 52mg IUS (only): licensed for HRT progestogen component. Kyleena 19.5mg is NOT sufficient

📊 Statistics

  • • 1 in 7 women develop breast cancer in lifetime
  • • ~77% UK 10-year survival overall; ~100% at stage 1
  • • PMB: 5-10% have endometrial cancer
  • • Breast pain alone (no lump): <1% cancer risk
  • • Fibroadenoma malignant transformation: 0.002–0.125%
  • • HRT + combined (synthetic progestogen): +4 extra breast cancers/1,000 over 5 years
  • • HRT + oestrogen-only: -4 (slightly protective) for breast cancer
  • • HRT fracture risk reduction: 28-40%
  • • POI: ~1% of women; menopausal symptoms average 7 years duration

🔑 HRT Rules

  • • Uterus present = combined HRT required
  • • No uterus = oestrogen-only HRT (safer for breast)
  • • Perimenopausal = sequential HRT (withdrawal bleed)
  • • Post-menopausal = continuous combined HRT (no bleed)
  • • Prefer transdermal oestrogen (no VTE risk unlike oral)
  • • Oral oestrogen contraindicated if BMI ≥30 or VTE risk factors
  • • No arbitrary 5-year HRT limit (NICE NG23 2024)
  • • FSH NOT needed for diagnosis in women ≥45 with typical symptoms
  • • POI: two FSH readings >40 IU/L, 4-6 weeks apart

🎭 SCA Hot Topics

•"I've found a lump" — Cancer Worry: Acknowledge fear, use warning shot if urgent referral needed. "I can see you're worried. The most important thing is to get it properly checked." Don't over-reassure before triple assessment.
•"Should I take HRT?" — Shared Decision Making: Demonstrate weighing benefits vs risks, personalised to patient. Mention transdermal preference, Utrogestan as safest progestogen, no arbitrary 5-year limit.
•Perimenopausal Depression: Woman ~50 on antidepressants for 2+ years with persistent symptoms. Recognise this may be perimenopause — discuss HRT trial as alternative. Shows breadth of GP thinking.
•Postmenopausal Bleeding on HRT: Beyond 3-6 months = investigate. 2WW referral. Don't assume it's "just the HRT" without investigation.
•Pelvic Examination Etiquette: Offer chaperone (document if declined), explain each step, trauma-informed approach, never assume consent from previous exams.

⚠️ Common Exam Traps

✗WRONG: "Breast pain = benign, no referral needed" — Always examine first. Lump may be present. Pain alone is rarely cancer (<1%) but examination cannot be skipped.
✗WRONG: "Painless lump = safer to watch" — Painless lump is MORE suspicious. Most cancers are painless. Refer urgently.
✗WRONG: "PMB — wait and see if it stops" — ALL PMB needs urgent investigation (2WW). Even spotting counts.
✗WRONG: "Abdominal swelling in a woman over 60 — probably weight gain" — This is ovarian cancer until proven otherwise.
✗WRONG: "HRT can only be given for 5 years" — NICE: no arbitrary limit. Duration = annual individual risk-benefit assessment.
✗WRONG: "Give SSRIs for perimenopausal mood symptoms" — HRT is first-line for low mood in perimenopause without prior depression (NICE NG23 2024).
✗WRONG: "Wild yam cream is a safe natural alternative to HRT" — Wild yam provides NO endometrial protection. It is NOT safe as a substitute for progestogen in women taking oestrogen.
✗WRONG: "Prescribe paroxetine for hot flushes in a woman on tamoxifen" — Paroxetine inhibits CYP2D6, reducing tamoxifen efficacy. Use venlafaxine, citalopram, or escitalopram.
✗WRONG: "Ibuprofen gel for mastalgia" — Evidence supports diclofenac 1% gel specifically (not ibuprofen gel) for breast pain.
💪

You've Got This!

Breast and gynaecology consultations don't have to be daunting

Key Takeaways

✓

Triple assessment is gold standard — never rely on one modality alone for breast lumps

✓

Painless breast lump = more suspicious for cancer — most cancers are painless, do not be falsely reassured

✓

Red flags require urgent action — PMB, breast lump ≥30yrs, visible cervical mass all need 2WW

✓

Woman ≥60 with abdominal swelling — think ovarian cancer first, not weight gain

✓

Dyspareunia tells a story — superficial vs deep point to very different diagnoses; always ask

✓

Perimenopause masquerades as depression — HRT, not SSRIs, is first-line for mood in perimenopause without prior depression (NICE 2024)

✓

Choose Utrogestan as progestogen wherever possible — body-identical, lowest breast cancer risk profile

✓

Transdermal oestrogen preferred — no VTE risk unlike oral, suitable even with BMI >30

✓

No arbitrary 5-year HRT limit — NICE supports continued use with annual individual risk-benefit review

✓

Wild yam cream provides NO endometrial protection — it is not a safe progestogen substitute

✓

Fezolinetant (Veoza) 45mg OD — new NICE-approved March 2026 NK3 antagonist for women unable to take HRT

✓

POI needs HRT until at least age 51 — even if asymptomatic, to protect bone, CVD, and cognitive health

Quick Reference Checklists

Every Breast Lump:

☑ History (painless? red flags? duration, changes)

☑ Examination (size, consistency, mobility, nodes)

☑ Refer for triple assessment (2WW if criteria met)

☑ Safety-net (return if changes)

☑ Address cancer fears — reassure but be honest

Every PMB:

☑ Confirm >12 months since LMP

☑ Exclude HRT-related (first 6 months only)

☑ Offer examination (speculum + bimanual)

☑ 2WW referral (unless clear HRT cause)

☑ Reassure most cases benign, but must investigate

Every Menopause Consultation:

☑ Assess symptom impact on quality of life

☑ Ask about dyspareunia (superficial vs deep)

☑ Ask about mood/cognition — consider HRT before SSRIs

☑ Discuss HRT risks/benefits — choose Utrogestan, prefer transdermal

☑ Review at 3 months, then annually

Every Pelvic Pain:

☑ Pregnancy test (ALWAYS if reproductive age)

☑ Exclude ectopic (positive test + pain = urgent)

☑ Ask about dyspareunia (often not volunteered)

☑ Examination (peritonism? cervical excitation?)

☑ Consider STI screen, USS, CA125

Remember: You're not expected to know everything

What matters is recognizing red flags, referring appropriately, communicating with empathy, and safety-netting effectively. Keep learning, keep reflecting, and trust your clinical judgment.

📚 Keep Learning 💪 Stay Confident ❤️ Care Compassionately

© 2026 Bradford VTS Clinical Knowledge. Last updated: 22 March 2026.

Based on NICE NG23 (updated November 2024), NICE CKS, British Menopause Society 2024-2026 guidance, and current peer-reviewed evidence.

This page is for educational purposes. Always refer to current NICE guidance and local protocols for individual patient management.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top

How IT ALL STARTED
WHAT WE'RE ABOUT
WHO ARE WE FOR?

Bradford VTS was created by Dr. Ramesh Mehay, a Programme Director for Bradford GP Training Scheme back in 2001. Over the years, it has seen many permutations.  At the time, there were very few resources for GP trainees and their trainers so Bradford decided to create one FOR EVERYONE. 

So, we see Bradford VTS as  the INDEPENDENT vocational training scheme website providing a wealth of free medical resources for GP trainees, their trainers and TPDs everywhere and anywhere.  We also welcome other health professionals – as we know the site is used by both those qualified and in training – such as Associate Physicians, ANPs, Medical & Nursing Students. 

Our fundamental belief is to openly and freely share knowledge to help learn and develop with each other.  Feel free to use the information – as long as it is not for a commercial purpose.   

We have a wealth of downloadable resources and we also welcome copyright-free educational material from all our users to help build our rich resource (send to bradfordvts@gmail.com).

Our sections on (medical) COMMUNICATION SKILLS and (medical) TEACHING & LEARNING are perhaps the best and most comprehensive on the world wide web (see white-on-black menu header section on the homepage).

Join our mailing list